Julie Grant, M.Phil, MBA

Canaan

Julie is a General Partner at Canaan where she leads investments and company formation efforts in biopharma that tangibly improve patient care. Since joining Canaan in 2013, Julie has incubated, financed and supported investments in multiple new biopharmaceutical companies including Solstice Oncology, Day One Biopharmaceuticals (DAWN), Vedana, Vima Therapeutics,  Vedana Therapeutics, Nocion, Synthekine, Protagonist (PTGX), Cellular Research (Acquired by Becton Dickinson), Dermira (DERM), Labrys Biologics (Acquired by Teva), CytomX (CTMX), and Unchained Labs. 

Prior to joining Canaan, Julie worked at Genentech bringing new oncology products to market in roles spanning business development, cross functional management and commercial. Julie serves on the National Cancer Advisory Board of the NCI.   She holds an M.B.A. from Stanford’s Graduate School of Business, a M.Phil. from Cambridge University in BioScience Enterprise and a B.S. in Molecular Biophysics and Biochemistry from Yale University.